Question explored with the scientific record
Statins
The short version: statins clearly cut heart attacks and strokes in people who already have heart disease, but the benefit shrinks to near nothing for healthy people, and the muscle and diabetes harms are real.
The strongest evidence is in sick hearts. In people with a recent acute coronary syndrome, intensive statins cut all-cause deaths from about 4.6% to 3.5% over two years [1]. In stable heart disease, the same intensive therapy did nothing for all-cause mortality [1]. Across 31 trials, statins cut total stroke and all-cause mortality modestly [4]. That is a real, hard-outcome benefit, and it is concentrated in secondary prevention.
For healthy people the picture is thinner and mostly observational. One large primary-prevention cohort found statin users had fewer heart attacks, but that is not a randomized trial [6]. The clearest primary-prevention signal came in people with high genetic risk, where benefit was largest, and smallest in low-risk people [6]. A 2022 cohort found the lowest death risk at a non-HDL cholesterol around 142-144 mg/dl, meaning very low cholesterol was not better [2].
The harms are not trivial. Intensive statins tripled liver enzyme events, from 0.4% to 1.4% [3]. High-intensity therapy raised muscle problems and elevated CK versus moderate [8]. New-onset diabetes rose with intensity, about 7.8% versus 5.8% in one post-heart-attack cohort [5], and pitavastatin had far less diabetes than atorvastatin or rosuvastatin [7]. A rare autoimmune muscle disease exists that persists after stopping the drug [9].
| Group | Outcome | Result |
|---|---|---|
| Recent ACS, intensive statin [1] | All-cause death | 4.6% → 3.5% |
| Stable heart disease, intensive [1] | All-cause death | No effect |
| Intensive vs moderate [3] | Liver enzyme events | 0.4% → 1.4% |
| High vs moderate intensity [8] | Any muscle problem | Small increase |
| Post-MI, high vs moderate [5] | New diabetes | 7.8% vs 5.8% |
My call: if you have had a heart attack or known coronary disease, the mortality and stroke benefit is real and worth the muscle and diabetes risk. If you are healthy with normal cholesterol, the randomized evidence for living longer is weak, and the harms are concrete. Confidence: moderate for secondary prevention, low for primary prevention in low-risk people.
Sources used 9
-
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Intensive statin therapy reduces all-cause mortality in patients with recent acute coronary syndromes but not in patients with stable coronary heart disease, while reducing MACE and heart failure admissions in both groups.
DOI: 10.1136/hrt.2006.112508 -
U-Shaped Relationship of Non-HDL Cholesterol With All-Cause and Cardiovascular Mortality in Men Without Statin Therapy
Non-HDL-C demonstrated a U-shaped relationship with all-cause and cardiovascular mortality in 12,574 US men without statin therapy, with lowest mortality risk at approximately 142-144 mg/dl.
DOI: 10.3389/fcvm.2022.903481 -
Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis
A systematic review and meta-analysis showing that statin therapy reduces all-cause mortality and stroke in patients with lower limb peripheral arterial disease, although evidence for cardiovascular mortality and myocardial infarction is less clear and overall study quality is l…
DOI: 10.1016/j.vph.2014.09.001 -
Statin Therapy and the Risk of Intracerebral Hemorrhage
In a meta-analysis of 31 statin RCTs, active therapy did not significantly increase intracerebral hemorrhage but reduced total stroke and all-cause mortality.
DOI: 10.1161/strokeaha.112.655894 -
Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study
This nationwide cohort study investigates the differential diabetogenic effects of statins based on their intensity and dose in patients with acute myocardial infarction, revealing that high-intensity statin therapy is associated with a higher incidence of new-onset diabetes mel…
DOI: 10.1038/s41598-024-67585-7 -
Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real‐World Population
In a real-world primary prevention cohort, a CHD polygenic risk score modified statin relative risk reduction for myocardial infarction, with greatest benefit at high PRS and attenuated benefit at low PRS.
DOI: 10.1002/cpt.2715 -
Effect of Pitavastatin Compared with Atorvastatin andRosuvastatin on New-Onset Diabetes Mellitus in PatientsWith Acute Myocardial Infarction
This study investigates the impact of moderate-intensity pitavastatin compared to atorvastatin and rosuvastatin on the incidence of new-onset diabetes mellitus in patients with acute myocardial infarction, finding that pitavastatin is associated with a significantly lower incide…
DOI: 10.1016/j.amjcard.2018.06.017 -
Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients
Network meta-analysis of 24 double-blinded RCTs (n=152 461) found small but significant increases in myalgia, any muscle symptoms, attrition and elevated CK with high versus moderate intensity statin therapy, with no significant excess for moderate intensity versus placebo.
DOI: 10.1136/bmjopen-2020-043714 -
Statin‐associated autoimmune myopathy and anti‐HMGCR autoantibodies
Anti-HMGCR autoantibodies mark a statin-associated autoimmune myopathy that persists after statin withdrawal, are absent in self-limited statin intolerance, and associate with HLA-DRB1*11:01.
DOI: 10.1002/mus.23854